ZAI LAB LIMITED Increase (Decrease) in Accounts Payable
ZAI LAB LIMITED (ZLAB) reported Increase (Decrease) in Accounts Payable of $2.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- ZAI LAB LIMITED increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.38M, a 136.73% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $4.26M, a 56.65% increase year-over-year.
- ZAI LAB LIMITED increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $20.35M.
- ZAI LAB LIMITED increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$6.90M, a 154.49% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in accounts payable for fiscal 2025 was $19.93M.
- ZAI LAB LIMITED increase (decrease) in accounts payable for fiscal 2024 was -$2.21M, a 106.00% decline from fiscal 2023.
- ZAI LAB LIMITED increase (decrease) in accounts payable for fiscal 2023 was $36.80M.
- ZAI LAB LIMITED increase (decrease) in accounts payable for fiscal 2022 was -$53.77M, a 184.65% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.88M 10-Q · filed 2026-08-06 | $23.23M derived: sum of 3 quarters · filed 2026-08-06 | $16.33M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $4.26M 10-Q · filed 2026-05-07 | $24.61M derived: sum of 2 quarters · filed 2026-05-07 | $17.71M derived: sum of 3 quarters · filed 2026-05-07 | $21.47M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $20.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.45M derived: sum of 2 quarters · filed 2026-02-26 | $17.21M derived: sum of 3 quarters · filed 2026-08-06 | $19.93M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$6.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.15M derived: sum of 2 quarters · filed 2026-08-06 | -$426.00K 10-Q · filed 2025-11-06 | -$9.18M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.47M 10-Q · filed 2026-08-06 | -$2.28M derived: sum of 3 quarters · filed 2026-08-06 | $10.38M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $2.72M 10-Q · filed 2026-05-07 | -$6.03M derived: sum of 2 quarters · filed 2026-05-07 | $6.63M derived: sum of 3 quarters · filed 2026-05-07 | $13.88M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.91M derived: sum of 2 quarters · filed 2026-02-26 | $11.16M derived: sum of 3 quarters · filed 2026-02-26 | -$2.21M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $12.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $19.91M derived: sum of 2 quarters · filed 2025-11-06 | $6.54M 10-Q · filed 2025-11-06 | $52.84M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $7.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$6.12M 10-Q · filed 2025-08-07 | $40.18M derived: sum of 3 quarters · filed 2026-02-26 | $27.65M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$13.37M 10-Q · filed 2025-05-08 | $32.93M derived: sum of 2 quarters · filed 2026-02-26 | $20.40M derived: sum of 3 quarters · filed 2026-02-26 | $23.76M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $46.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $33.77M derived: sum of 2 quarters · filed 2026-02-26 | $37.13M derived: sum of 3 quarters · filed 2026-02-26 | $36.80M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$12.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$9.17M derived: sum of 2 quarters · filed 2024-11-12 | -$9.49M 10-Q · filed 2024-11-12 | -$34.42M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.04M 10-Q · filed 2024-08-06 | -$21.89M derived: sum of 3 quarters · filed 2025-02-27 | -$33.02M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$327.00K 10-Q · filed 2024-05-08 | -$25.25M derived: sum of 2 quarters · filed 2025-02-27 | -$36.38M derived: sum of 3 quarters · filed 2025-02-27 | -$26.10M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | -$24.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$36.05M derived: sum of 2 quarters · filed 2025-02-27 | -$25.77M derived: sum of 3 quarters · filed 2025-02-27 | -$53.77M 10-K · filed 2025-02-27 | |
| 2022-09-30 | -$11.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$848.00K derived: sum of 2 quarters · filed 2023-11-07 | -$28.85M 10-Q · filed 2023-11-07 | $45.91M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $10.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$17.72M 10-Q · filed 2023-08-07 | $57.04M derived: sum of 3 quarters · filed 2024-02-27 | -$17.18M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | -$28.00M 10-Q · filed 2023-05-09 | $46.76M derived: sum of 2 quarters · filed 2024-02-27 | -$27.46M derived: sum of 3 quarters · filed 2024-02-27 | $56.75M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $74.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $542.00K derived: sum of 2 quarters · filed 2024-02-27 | $84.75M derived: sum of 3 quarters · filed 2024-02-27 | $63.52M 10-K · filed 2024-02-27 | |
| 2021-09-30 | -$74.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $9.99M derived: sum of 2 quarters · filed 2022-11-09 | -$11.23M 10-Q · filed 2022-11-09 | $23.53M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $84.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $62.98M 10-Q · filed 2022-08-09 | $97.74M derived: sum of 3 quarters · filed 2023-03-01 | $93.23M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | -$21.23M 10-Q · filed 2022-05-10 | $13.54M derived: sum of 2 quarters · filed 2023-03-01 | $9.02M derived: sum of 3 quarters · filed 2023-03-01 | $14.26M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $34.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $30.25M derived: sum of 2 quarters · filed 2023-03-01 | $35.49M derived: sum of 3 quarters · filed 2023-03-01 | $39.98M 10-K · filed 2023-03-01 | |
| 2020-09-30 | -$4.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $722.00K derived: sum of 2 quarters · filed 2021-11-09 | $5.22M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $5.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $9.73M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $4.50M 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | -$14.77M 10-K · filed 2022-03-01 | ||||
| 2019-06-30 | -$9.71M 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $28.46M 10-K · filed 2021-03-01 | $28.46M 20-F · filed 2019-03-29 | |||
| 2017-12-31 | $8.44M 20-F · filed 2020-04-29 | $8.44M 20-F · filed 2018-04-30 | |||
| 2016-12-31 | -$929.72K 20-F · filed 2019-03-29 | ||||
| 2015-12-31 | $1.29M 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |